322 related articles for article (PubMed ID: 12685503)
21. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
22. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
23. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
24. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
25. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
27. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
[TBL] [Abstract][Full Text] [Related]
28. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
Barecki ME; Casciano CN; Johnson WW; Clement RP
Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.
Polasek TM; Elliot DJ; Somogyi AA; Gillam EM; Lewis BC; Miners JO
Br J Clin Pharmacol; 2006 May; 61(5):570-84. PubMed ID: 16669850
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
31. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
32. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
33. Inhibition selectivity of grapefruit juice components on human cytochromes P450.
Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y
Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553
[TBL] [Abstract][Full Text] [Related]
34. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
35. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
36. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Ko JW; Desta Z; Soukhova NV; Tracy T; Flockhart DA
Br J Clin Pharmacol; 2000 Apr; 49(4):343-51. PubMed ID: 10759690
[TBL] [Abstract][Full Text] [Related]
37. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
39. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
40. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.
Liu L; Sun S; Rui H; Li X
Pharm Biol; 2017 Dec; 55(1):1868-1874. PubMed ID: 28614988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
